Tarec Christoffer El-Galaly

List of Publications by Year
in descending order

135 papers	**2,544** citations

201575

27 h-index

233338

45 g-index

136 all docs	**136** docs citations

136 times ranked

3549 citing authors

#	Article	IF	Citations
1	Routine Bone Marrow Biopsy Has Little or No Therapeutic Consequence for Positron Emission Tomography/Computed Tomography–Staged Treatment-Naive Patients With Hodgkin Lymphoma. Journal of Clinical Oncology, 2012, 30, 4508-4514.	0.8	252
2	Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies. Lancet Haematology,the, 2018, 5, e563-e598.	2.2	97
3	Diffuse Large B-Cell Lymphoma Classification System That Associates Normal B-Cell Subset Phenotypes With Prognosis. Journal of Clinical Oncology, 2015, 33, 1379-1388.	0.8	94
4	Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma. European Journal of Cancer, 2018, 93, 57-68.	1.3	90
5	Definitive radiotherapy for localized follicular lymphoma staged by 18F-FDG PET-CT: a collaborative study by ILROG. Blood, 2019, 133, 237-245.	0.6	85
6	<scp>FDG</scp>â€‹<scp>PET</scp>/<scp>CT</scp> in the management of lymphomas: current status and future directions. Journal of Internal Medicine, 2018, 284, 358-376.	2.7	79
7	Routine Imaging for Diffuse Large B-Cell Lymphoma in First Complete Remission Does Not Improve Post-Treatment Survival: A Danish–Swedish Population-Based Study. Journal of Clinical Oncology, 2015, 33, 3993-3998.	0.8	74
8	Positron emission tomography/computed tomography surveillance in patients with Hodgkin lymphoma in first remission has a low positive predictive value and high costs. Haematologica, 2012, 97, 931-936.	1.7	73
9	Minimal Loss of Lifetime for Patients With Diffuse Large B-Cell Lymphoma in Remission and Event Free 24 Months After Treatment: A Danish Population-Based Study. Journal of Clinical Oncology, 2017, 35, 778-784.	0.8	72
10	Outcome prediction by extranodal involvement, IPI, Râ€‰IPI, and NCCNâ€‰IPI in the PET/CT and rituximab era: A <scp>D</scp>anishâ€“<scp>C</scp>anadian study of 443 patients with diffuseâ€‰large <scp>B</scp>â€‰cell lymphoma. American Journal of Hematology, 2015, 90, 1041-1046.	2.0	71
11	The Danish National Lymphoma Registry: Coverage and Data Quality. PLoS ONE, 2016, 11, e0157999.	1.1	66
12	The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: An international multicenter study of 1532 patients treated with chemoimmunotherapy. European Journal of Cancer, 2017, 75, 195-203.	1.3	65
13	Treatment strategies and outcomes in diffuse large B-cell lymphoma among 1011 patients aged 75 years or older: A Danish population-based cohort study. European Journal of Cancer, 2018, 99, 86-96.	1.3	59
14	miR-155 as a Biomarker in B-Cell Malignancies. BioMed Research International, 2016, 2016, 1-14.	0.9	56
15	The myeloma stem cell concept, revisited: from phenomenology to operational terms. Haematologica, 2016, 101, 1451-1459.	1.7	55
16	Utility of interim and endâ€‰ofâ€‰treatment PET/CT in peripheral Tâ€‰cell lymphomas: A review of 124 patients. American Journal of Hematology, 2015, 90, 975-980.	2.0	51
17	Role of routine imaging in detecting recurrent lymphoma: A review of 258 patients with relapsed aggressive nonâ€‰Hodgkin and Hodgkin lymphoma. American Journal of Hematology, 2014, 89, 575-580.	2.0	49
18	PET/CT for Staging; Past, Present, and Future. Seminars in Nuclear Medicine, 2018, 48, 4-16.	2.5	48

#	Article	IF	Citations
19	Predictive Value of PET Response Combined with Baseline Metabolic Tumor Volume in Peripheral T-Cell Lymphoma Patients. Journal of Nuclear Medicine, 2018, 59, 589-595.	2.8	48
20	Clinical impact of clonal hematopoiesis in patients with lymphoma undergoing ASCT: a national population-based cohort study. Leukemia, 2020, 34, 3256-3268.	3.3	46
21	Efficacy of routine surveillance with positron emission tomography/computed tomography in aggressive non-Hodgkin lymphoma in complete remission: status in a single center. Leukemia and Lymphoma, 2011, 52, 597-603.	0.6	45
22	Predicting response to multidrug regimens in cancer patients using cell line experiments and regularised regression models. BMC Cancer, 2015, 15, 235.	1.1	44
23	Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients. Blood, 2022, 139, 2499-2511.	0.6	42
24	COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study. Blood Advances, 2019, 3, 2013-2021.	2.5	40
25	Cumulative anthracycline exposure and risk of cardiotoxicity; a Danish nationwide cohort study of 2440 lymphoma patients treated with or without anthracyclines. British Journal of Haematology, 2018, 183, 717-726.	1.2	37
26	Burkitt Lymphoma International Prognostic Index. Journal of Clinical Oncology, 2021, 39, 1129-1138.	0.8	37
27	Implementing the FAIR Data Principles in precision oncology: review of supporting initiatives. Briefings in Bioinformatics, 2020, 21, 936-945.	3.2	35
28	Uterine, but not ovarian, female reproductive organ involvement at presentation by diffuse large B‑cell lymphoma is associated with poor outcomes and a high frequency of secondary <scp>CNS</scp> involvement. British Journal of Haematology, 2016, 175, 876-883.	1.2	34
29	No survival benefit associated with routine surveillance imaging for Hodgkin lymphoma in first remission: a Danish‑Swedish population‑based observational study. British Journal of Haematology, 2016, 173, 236-244.	1.2	28
30	Simplicity at the cost of predictive accuracy in diffuse large B‑cell lymphoma: a critical assessment of the R‑<scp>IPI</scp>,<scp> IPI</scp>, and <scp>NCCN</scp>‑<scp>IPI</scp>. Cancer Medicine, 2018, 7, 114-122.	1.3	28
31	A population‑based study of prognosis in advanced stage follicular lymphoma managed by watch and wait. British Journal of Haematology, 2015, 169, 435-444.	1.2	27
32	Optimizing Outcome Prediction in Diffuse Large B-Cell Lymphoma by Use of Machine Learning and Nationwide Lymphoma Registries: A Nordic Lymphoma Group Study. JCO Clinical Cancer Informatics, 2018, 2, 1-13.	1.0	27
33	Single nucleotide polymorphisms and the risk of venous thrombosis: results from a Danish case‑cohort study. British Journal of Haematology, 2013, 160, 838-841.	1.2	26
34	R-CHOP(-like) treatment of diffuse large B-cell lymphoma significantly reduces CT-assessed vertebral bone density: a single center study of 111 patients. Leukemia and Lymphoma, 2017, 58, 1105-1113.	0.6	26
35	Impact of R-CHOP dose intensity on survival outcomes in diffuse large B-cell lymphoma: a systematic review. Blood Advances, 2021, 5, 2426-2437.	2.5	24
36	Impact of ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography staging in newly diagnosed classical Hodgkin lymphoma: fewer cases with stage I disease and more with skeletal involvement. Leukemia and Lymphoma, 2014, 55, 2349-2355.	0.6	23

#	Article	IF	Citations
37	Relapse Risk and Loss of Lifetime After Modern Combined Modality Treatment of Young Patients With Hodgkin Lymphoma: A Nordic Lymphoma Epidemiology Group Study. Journal of Clinical Oncology, 2019, 37, 703-713.	0.8	22
38	Outcome of peripheral T-cell lymphoma in first complete remission: a Danish-Swedish population-based study. Leukemia and Lymphoma, 2017, 58, 2815-2823.	0.6	19
39	Salvage Treatment and Survival for Relapsed Follicular Lymphoma Following Primary Radiation Therapy: A Collaborative Study on Behalf of ILROG. International Journal of Radiation Oncology Biology Physics, 2019, 104, 522-529.	0.4	16
40	Increased risk of osteoporosis following commonly used first-line treatments for lymphoma: a Danish Nationwide Cohort Study. Leukemia and Lymphoma, 2020, 61, 1345-1354.	0.6	16
41	Outcomes of relapsed/refractory diffuse large Bâ€cell lymphoma and influence of chimaeric antigen receptor T trial eligibility criteria in second lineâ€"A populationâ€based study of 736 patients. British Journal of Haematology, 2022, 198, 267-277.	1.2	16
42	Human B-cell cancer cell lines as a preclinical model for studies of drug effect in diffuse large B-cell lymphoma and multiple myeloma. Experimental Hematology, 2014, 42, 927-938.	0.2	15
43	Clinical characteristics and outcomes of patients with Hodgkin lymphoma with central nervous system involvement: An international multicenter collaboration. American Journal of Hematology, 2016, 91, 894-899.	2.0	15
44	High-Dose Methotrexate Is Not Associated with Reduction in CNS Relapse in Patients with Aggressive B-Cell Lymphoma: An International Retrospective Study of 2300 High-Risk Patients. Blood, 2021, 138, 181-181.	0.6	14
45	Risk of death, relapse or progression, and loss of life expectancy at different progression-free survival milestones in primary central nervous system lymphoma. Leukemia and Lymphoma, 2019, 60, 2516-2523.	0.6	13
46	Depression and anxiety in Hodgkin lymphoma patients: A Danish nationwide cohort study of 945 patients. Cancer Medicine, 2020, 9, 4395-4404.	1.3	13
47	Imaging of Non-Hodgkin Lymphomas: Diagnosis and Response-Adapted Strategies. Cancer Treatment and Research, 2015, 165, 125-146.	0.2	12
48	On estimating the time to statistical cure. BMC Medical Research Methodology, 2020, 20, 71.	1.4	12
49	Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 realâ€world patients. British Journal of Haematology, 2020, 189, 661-671.	1.2	12
50	Incidence and time trends of second primary malignancies after non-Hodgkin lymphoma: a Swedish population-based study. Blood Advances, 2022, 6, 2657-2666.	2.5	12
51	Estimating the loss of lifetime function using flexible parametric relative survival models. BMC Medical Research Methodology, 2019, 19, 23.	1.4	11
52	Preâ€treatment total metabolic tumour volumes in lymphoma: Does quantity matter?. British Journal of Haematology, 2022, 197, 139-155.	1.2	11
53	Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies. Lancet Haematology,the, 2022, 9, e374-e384.	2.2	11
54	Mantle Cell Lymphoma of Mucosaâ€Associated Lymphoid Tissue: A European Mantle Cell Lymphoma Network Study. HemaSphere, 2020, 4, e302.	1.2	10

#	Article	IF	Citations
55	The prognostic effect of smoking status on intensively treated acute myeloid leukaemia â€" A Danish nationwide cohort study. British Journal of Haematology, 2020, 190, 236-243.	1.2	10
56	Parenthood Rates and Use of Assisted Reproductive Techniques in Younger Hodgkin Lymphoma Survivors: A Danish Population-Based Study. Journal of Clinical Oncology, 2021, 39, 3463-3472.	0.8	10
57	The MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 study. Blood Advances, 2022, 6, 1162-1174.	2.5	10
58	The application of human phase 0 microdosing trials: A systematic review and perspectives. Leukemia and Lymphoma, 2016, 57, 1281-1290.	0.6	9
59	A comparative study of standardized quantitative and visual assessment for predicting tumor volume and outcome in newly diagnosed diffuse large B-cell lymphoma staged with 18F-FDG PET/CT. EJNMMI Research, 2019, 9, 36.	1.1	9
60	Potentials, challenges and future of chimeric antigen receptor T-cell therapy in non-Hodgkin lymphomas. Acta OncolÃ³gica, 2020, 59, 766-774.	0.8	9
61	Temporal changes in survival among adult patients with acute myeloid leukaemia in the period 2000â€"2016: a Danish populationâ€'based study. British Journal of Haematology, 2021, 193, 482-487.	1.2	9
62	Development of a Precision Medicine Workflow in Hematological Cancers, Aalborg University Hospital, Denmark. Cancers, 2020, 12, 312.	1.7	8
63	Relapsed/Refractory International Prognostic Index (R/<scp>Râ€'PI</scp>): An international prognostic calculator for relapsed/refractory diffuse large Bâ€'cell lymphoma. American Journal of Hematology, 2021, 96, 599-605.	2.0	8
64	Subtype assignment of CLL based on B-cell subset associated gene signatures from normal bone marrow â€" A proof of concept study. PLoS ONE, 2018, 13, e0193249.	1.1	8
65	Prognostic impact of clinician-based interpretation of18F-fluorodeoxyglucose positron emission tomography/computed tomography reports obtained in patients with newly diagnosed diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2014, 55, 1563-1569.	0.6	7
66	Circulating tumor necrosis factor-Î± and YKL-40 level is associated with remission status following salvage therapy in relapsed non-Hodgkin lymphoma. Leukemia and Lymphoma, 2015, 56, 2476-2478.	0.6	7
67	hemaClass.org: Online One-By-One Microarray Normalization and Classification of Hematological Cancers for Precision Medicine. PLoS ONE, 2016, 11, e0163711.	1.1	7
68	Little value of surveillance magnetic resonance imaging for primary <scp>CNS</scp> lymphomas in first remission: results from a Danish Multicentre Study. British Journal of Haematology, 2017, 176, 671-673.	1.2	7
69	Real world data on rituximab maintenance therapy after frontline immunochemotherapy in grade 1â€"3a follicular lymphoma. British Journal of Haematology, 2018, 182, 297-301.	1.2	7
70	Real world data as a key element in precision medicine for lymphoid malignancies: potentials and pitfalls. British Journal of Haematology, 2019, 186, 409-419.	1.2	7
71	Clinical prognostic scores are poor predictors of overall survival in various types of malignant lymphomas. Leukemia and Lymphoma, 2019, 60, 1580-1583.	0.6	6
72	Clinical characteristics and outcomes among 2347 patients aged â‰¥85Âyears with major lymphoma subtypes: a Nordic Lymphoma Group study. British Journal of Haematology, 2021, 192, 551-559.	1.2	6

#	Article	IF	Citations
73	Mental health among patients with non‐Hodgkin lymphoma: A Danish nationwide study of psychotropic drug use in 8750 patients and 43‰750 matched comparators. American Journal of Hematology, 2022, 97, 749-761.	2.0	6
74	A prognostic model integrating PET‐derived metrics and image texture analyses with clinical risk factors from GOYA. EJHaem, 2022, 3, 406-414.	0.4	6
75	Bone health and glucocorticoid‐containing lymphoma therapy â€" a review of risk factors and preventative measures. British Journal of Haematology, 2022, 198, 431-442.	1.2	6
76	Risk for Myocardial Infarction Following 5-Fluorouracil Treatment in Patients With Gastrointestinal Cancer. JACC: CardioOncology, 2021, 3, 725-733.	1.7	6
77	The mutational profile of immune surveillance genes in diagnostic and refractory/relapsed DLBCLs. BMC Cancer, 2021, 21, 829.	1.1	5
78	Evolution of relative survival for acute promyelocytic leukemia patients alive at landmark time-points: a population-based study. Leukemia, 2018, 32, 2263-2303.	3.3	4
79	Limited value of routine follow-up visits in chronic lymphocytic leukemia managed initially by watch and wait: A North Denmark population-based study. PLoS ONE, 2018, 13, e0208180.	1.1	4
80	A randomized trial of alendronate as prophylaxis against loss in bone mineral density following lymphoma treatment. Blood Advances, 2022, 6, 2549-2556.	2.5	4
81	Characterization of memory B cells from thymus and its impact for DLBCL classification. Experimental Hematology, 2016, 44, 982-990.e11.	0.2	3
82	Normal myeloid progenitor cell subset-associated gene signatures for acute myeloid leukaemia subtyping with prognostic impact. PLoS ONE, 2020, 15, e0229593.	1.1	3
83	Mutational landscape of immune surveillance genes in diffuse large B-cell lymphoma. Expert Review of Hematology, 2020, 13, 655-668.	1.0	3
84	Detecting deviations from the efficacy and safety results of single‐arm trials using real‐world data: The case of a CAR‐T cell therapy in B‐cell lymphoma. Pharmacoepidemiology and Drug Safety, 2021, 30, 514-519.	0.9	3
85	Treatment intensity and survival trends among real-world elderly AML patients diagnosed in the period 2001â€"2016: a Danish nationwide cohort study. Leukemia and Lymphoma, 2021, 62, 2014-2017.	0.6	3
86	Normalization of Survival and No Relapses after One Year in Adult Burkitt Lymphoma Patients Treated with Intensive Immunochemotherapy: An International Study of 159 Real-World Patients. Blood, 2018, 132, 452-452.	0.6	3
87	Patients in complete remission after R-CHOP(-like) therapy for diffuse large B-cell lymphoma have limited excess use of health care services in Denmark. Blood Cancer Journal, 2022, 12, 16.	2.8	3
88	Follicular Lymphoma Treated with First-Line Immunochemotherapy: A Review of PET/CT in Patients Who Did Not Achieve a Complete Metabolic Response in the GALLIUM Study. Journal of Nuclear Medicine, 2022, 63, 1149-1154.	2.8	3
89	Molecular classification of tissue from a transformed non-Hogkinâ€™s lymphoma case with unexpected long-time remission. Experimental Hematology and Oncology, 2017, 6, 3.	2.0	2
90	Anthropometrics and prognosis in diffuse large B‐cell lymphoma: a multicentre study of 653 patients. European Journal of Haematology, 2017, 98, 355-362.	1.1	2

#	Article	IF	Citations
91	Monitoring CAR-T-Cell Therapies Using the Nordic Healthcare Databases. Pharmaceutical Medicine, 2019, 33, 83-88.	1.0	2
92	An International Collaborative Study of Outcome and Prognostic Factors in Patients with Secondary CNS Involvement By Diffuse Large B-Cell Lymphoma. Blood, 2016, 128, 1874-1874.	0.6	2
93	A Diffuse Large B-Cell Lymphoma Classification System That Associates Normal B-Cell Subset Phenotypes with Prognosis. Blood, 2014, 124, 2973-2973.	0.6	2
94	Late relapses in Hodgkin lymphoma â€" should we search for the needle in the haystack?. British Journal of Haematology, 2022, 198, 11-13.	1.2	2
95	Shared care follow-up of patients with B-cell neoplasms based on nurse-led telephone consultations and PRO-data: a feasibility study from the North Denmark Region. BMC Health Services Research, 2020, 20, 1047.	0.9	1
96	Hematological cancer survivorsâ€™ experiences of participating in a shared care follow-upâ€"an exploratory interview study. Journal of Cancer Survivorship, 2021, 15, 620-629.	1.5	1
97	Relapse Risk and Loss in Expectation of Lifetime in Young Classical Hodgkin Lymphoma Patients - a Nordic Lymphoma Group Study of 2,582 Patients. Blood, 2018, 132, 930-930.	0.6	1
98	The Absolute Number of Extranodal Sites Detected By PET-CT Is a Powerful Predictor of Secondary Central Nervous System Involvement in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP. Blood, 2015, 126, 3905-3905.	0.6	1
99	Routine Bone Marrow Biopsy Adds Little Diagnostic Information in Patients with Newly Diagnosed Hodgkin Lymphoma Undergoing PET/CT Staging. Blood, 2011, 118, 2627-2627.	0.6	1
100	Role of Bone Marrow Biopsy in the Staging of Diffuse Large B-Cell Lymphoma in the PET/CT Era. Blood, 2014, 124, 2960-2960.	0.6	1
101	Prognostic Impact of Extranodal Diffuse Large B-Cell Lymphoma in the Era of Immunochemotherapy and PET/CT Staging. Blood, 2014, 124, 1630-1630.	0.6	1
102	A Multiple Myeloma Classification System That Associates Normal Bone Marrow B-Cell Subset Phenotypes with Disease Stage and Prognosis. Blood, 2014, 124, 3352-3352.	0.6	1
103	Clinical Impact of Clonal Hematopoiesis after Autologous Stem Cell Transplantation for Lymphoma: A National Population-Based Cohort Study. Blood, 2018, 132, 607-607.	0.6	1
104	Patient-reported outcomes in patients with hematological relapse or progressive disease: a longitudinal observational study. Health and Quality of Life Outcomes, 2021, 19, 251.	1.0	1
105	The Impact of Trial Eligibility Criteria on Outcomes in a Nationwide Cohort of Newly Diagnosed DLBCL Patients Treated with R-CHOP. Blood, 2021, 138, 53-53.	0.6	1
106	Event-Free and Overall Survival in over 6,000 Patients Treated with Frontline Immunochemotherapy for Follicular Lymphoma between 2002-2018: First Report from the International FLIPI24 Consortium. Blood, 2021, 138, 3527-3527.	0.6	1
107	Early Integration of High Dose Methotrexate to Frontline DLBCL Therapy Does Not Impact CNS Relapse Compared to End of Treatment Delivery: A Multicentre International Analysis of 1384 Patients. Blood, 2021, 138, 452-452.	0.6	1
108	TRAIL Score: A Simple Model to Predict Immunochemotherapy Tolerability in Patients With Diffuse Large B-Cell Lymphoma. JCO Clinical Cancer Informatics, 2022, 6, e2100121.	1.0	1

#	Article	IF	Citations
109	Level of unique T cell clonotypes is associated with clonal hematopoiesis and survival in patients with lymphoma undergoing ASCT. Bone Marrow Transplantation, 2022, , .	1.3	1
110	Psychotropic Drug Use in Acute Myeloid Leukaemia (AML) and Myelodysplastic Syndrome (MDS): A Danish Nationwide Matched Cohort Study of 2404 AML and 1307 MDS Patients. Clinical Epidemiology, 2022, Volume 14, 225-237.	1.5	1
111	Reply to H.J adams et al: â€œIs FDG-PET/CT a sensitive and specific method for the detection of extranodal involvement in diffuse large B-cell lymphoma?â€. American Journal of Hematology, 2016, 91, E2-E3.	2.0	0
112	To maintain or not, that is the question. British Journal of Haematology, 2016, 174, 321-322.	1.2	0
113	Blood on the tracks â€" toward precision medicine. Leukemia and Lymphoma, 2016, 57, 1753-1754.	0.6	0
114	Questioning the value of routine imaging for patients with mantle cell lymphoma in first remission. Leukemia and Lymphoma, 2018, 59, 775-777.	0.6	0
115	No differential overall or relative survival effect of rituximab in male and female patients with diffuse large B-cell lymphoma: a Danish population-based study of 3783 patients. Leukemia and Lymphoma, 2019, 60, 2798-2801.	0.6	0
116	Mantle cell lymphoma â€" where precision medicine based on responseâ€adapted treatment strategies could show its full worth. British Journal of Haematology, 2020, 189, 600-602.	1.2	0
117	Routine imaging for disease surveillance in follicular lymphomaâ€"To comfort the patients or their doctors?. Cancer, 2021, 127, 3298-3301.	2.0	0
118	Direct costs of antineoplastic and supportive treatment for progressive multiple myeloma in a tax-based health system. Future Oncology, 2021, 17, 3331-3341.	1.1	0
119	Prognostic Impact of Clinician-Based Interpretation of FDG-PET/CT Reports Obtained in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma.. Blood, 2012, 120, 2646-2646.	0.6	0
120	Clinical Features and Outcome in Newly Diagnosed Hodgkin Lymphoma Patients Presenting with PET/CT-Ascertained Focal Skeletal Lesions.. Blood, 2012, 120, 2637-2637.	0.6	0
121	Disease Extent in Newly Diagnosed Hodgkin Lymphoma: A Comparison of CT and PET/CT Staged Patients. Blood, 2012, 120, 1532-1532.	0.6	0
122	The International Prognostic Index Predicts Outcome In Patients With Untreated Nodal Peripheral T-Cell Lymphomas Staged With PET/CT. Blood, 2013, 122, 5077-5077.	0.6	0
123	Clinical Characteristics and Outcomes of Patients with Hodgkin Lymphoma with Central Nervous System Involvement: An International Multicenter Collaboration. Blood, 2015, 126, 3865-3865.	0.6	0
124	Subtyping of B-Cell Malignancies By B-Cell Subset Associated Gene Signatures (BAGS), Generated from Human Primary and Secondary Lymphoid Organs.. Blood, 2015, 126, 5347-5347.	0.6	0
125	PET/CT for HL Staging. , 2016, , 1-13.		0
126	Normal B-Cell Gene Expression Signatures Classifies Chronic Lymphocytic Leukemia into Distinct Subtypes - Indication of Plasticity. Blood, 2016, 128, 2017-2017.	0.6	0

#	ARTICLE	IF	CITATIONS
127	Risk of Death, Relapse or Progression, and Loss of Life Expectancy at Different Progression-Free Survival Milestones in Primary Central Nervous System Lymphoma. Blood, 2018, 132, 1699-1699.	0.6	0
128	Risk of Incident Diabetes and Dysregulated Pre-Existing Diabetes Mellitus in Newly Diagnosed Lymphoma Patients Treated with Steroid-Containing Immunochemotherapy: A Danish Population-Based Study. Blood, 2021, 138, 454-454.	0.6	0
129	Sex Differences in Lymphoma Incidence and Excess Mortality By Subtype: A Comprehensive National Study. Blood, 2021, 138, 2534-2534.	0.6	0
130	A Randomized Placebo-Controlled Trial of Primary Prophylaxis with Weekly Alendronateâ€ˆAgainst Glucocorticoid-Induced Osteoporosis in Lymphoma Patients Treated with Steroid-Containing Chemotherapy.. Blood, 2021, 138, 456-456.	0.6	0
131	Mental Health Among Patients with Non-Hodgkin Lymphoma: A Danish Nationwide Study of Psychotropic Drug Use in 7,201 Patients and 36,005 Matched Comparators. Blood, 2021, 138, 51-51.	0.6	0
132	Hodgkin Lymphoma: Recent Progress in Overall Management. , 0, , 83-116.		0
133	Level of Unique T-Cell Clonotypes Are Associated with Clonal Hematopoiesis and Survival in Patients with Lymphoma Intended for Autologous Stem Cell Transplant. Blood, 2021, 138, 3942-3942.	0.6	0
134	The Burkitt Lymphoma International Prognostic Index (BL-IPI). Blood, 2020, 136, 46-49.	0.6	0
135	Cardiovascular diseases in elderly survivors of diffuse large B-cell lymphoma: a Danish population-based cohort study. Leukemia and Lymphoma, 2022, , 1-10.	0.6	0